UCB4594
- Generic Name
- UCB4594
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Phase 1
Recruiting
- Conditions
- Advanced Solid TumoursSquamous Cell Carcinoma of Head and NeckCarcinoma, Non-Small-Cell LungColorectal NeoplasmsTriple Negative Breast NeoplasmsCarcinoma, Renal Cell (Clear Cell Only)Esophageal NeoplasmsStomach Neoplasms (Excluding Gastrointestinal Stromal Tumors)Uterine Cervical NeoplasmsOvarian Neoplasms
- Interventions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 167
- Registration Number
- NCT06380816
- Locations
- 🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom
🇬🇧University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath